-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the support of policies and capital, China's innovative drugs have developed rapid.
Especially after 2015, under the promotion of policies and capital support, China's innovative drug industry has rapidly increased the number of INDs, NDAs, and approva.
So far, there have been more than 70 domestically produced Class 1 new drugs (in terms of varieties + enterprises, including Class 1, Category 1, Category 2, Category 3, Category 5 (excluding vaccines, the same below) were approved for marketing, accounting for nearly half of the total approved domestic Category 1 new dru.
At present, among the domestic Class 1 new drugs that have been approved and commercialized, more than 40 of them will be in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) terminals in 202 The total sales of urban physical pharmacy terminals and Chinese online pharmacy terminals (hereinafter collectively referred to as domestic sales) exceeded 100 million yu.
The total sales volume of the top 20 products in sales exceeds 40 billion yuan, of which 19 drugs have sales of 1 billion yuan or more, and 3 are more than 3 billion yuan, namely Anroti Hydrochloride from Chia Tai Tianqing Pharmaceutica.
Ni Capsule, Hengrui Medicine's camrelizumab for injection, Sansheng Pharmaceutical's recombinant human thrombopoietin injection (TPIA.
In addition, it is worth mentioning that with the help of medical insurance, the sales of Cinda's sintilimab injection in 2021 will also reach nearly 3 billion yu.
Specifically, Chia Tai Tianqing Pharmaceutical's Anlotinib Hydrochloride Capsules was approved for marketing in May 2018, and was included in the National Medical Insurance Category B catalog through negotiation in the same year, and 5 indications have been achieved so f.
According to data from Min.
com, Anlotinib became a blockbuster as soon as it was list.
Its domestic sales exceeded 700 million yuan in its first year of listing (about half a yea.
It will exceed 4 billion yuan for the first time in 2020, and it will be expanded in 202 Hengrui Medicine's camrelizumab, the third domestically-made PD-1 mAb approved for marketing, was approved in May 201 Hengrui Medicine did not disclose the sales revenue of camrelizumab in its 2021 annual report, but the disclosed sales volume was 4143 million bottles, a year-on-year increase of 367
If calculated according to the medical insurance price of 2928 yuan/bottle, the sales revenue is about 141 billion yu.
Even with a year-on-year decline, it is still the one with higher sales among the four major domestic PD-1 mA.
According to the annual report released by 3SBio, in 2021, 3SBio achieved a total operating income of approximately RMB 38 billion, an increase of 12% over the same period last year; net profit attributable to the parent was RMB 65 billion, an increase of 96% over the same period last ye.
In 2021, 3SBio's main business revenue will maintain growth for 5 consecutive years, with a compound annual growth rate of 1
The sales revenue of core products will achieve strong double-digit growth, and the gross profit margin will be stable at over 8
Ability is outstandi.
Among them, TPIAO achieved sales revenue of 08 billion yuan, a year-on-year increase of 15%, with a market share of 7
Innovent Bio's 2021 annual report did not disclose the specific sales of the company's sintilimab, but it stated that "the company's annual operating income was 261 billion yuan, and the annual product revenue was about 001 billion yu.
The leading product Daboshu is on sa.
Both revenue and sales volume maintained strong growth, and other products also contributed to the strong growth in revenue, and the revenue contribution accounted for about 30% of the total annual product reven.
” Based on this calculation, the sales of Innovent Bio’s sintilimab in 2021 will account for the annual share of The total product revenue is about 70%, and the revenue is about 8 billion yuan, with a year-on-year growth rate of more than 2
In general, with the continuous improvement of the innovation capabilities of domestic pharmaceutical companies, more and more innovative drugs have begun to be launched at an accelerated pa.
However, the successful launch of innovative drugs is not the e.
What is more important is the second half, that is, to recover R&D costs through successful commercialization, and to obtain as much profit as possible, use it for more newer R&D projects, and promote the sustainable development of pharmaceutical compani.
The industry believes that from the current point of view, the road to commercialization of domestic innovative drugs can be expected in the future, but further efforts are needed in terms of indications and targets of innovative dru.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Especially after 2015, under the promotion of policies and capital support, China's innovative drug industry has rapidly increased the number of INDs, NDAs, and approva.
So far, there have been more than 70 domestically produced Class 1 new drugs (in terms of varieties + enterprises, including Class 1, Category 1, Category 2, Category 3, Category 5 (excluding vaccines, the same below) were approved for marketing, accounting for nearly half of the total approved domestic Category 1 new dru.
At present, among the domestic Class 1 new drugs that have been approved and commercialized, more than 40 of them will be in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) terminals in 202 The total sales of urban physical pharmacy terminals and Chinese online pharmacy terminals (hereinafter collectively referred to as domestic sales) exceeded 100 million yu.
The total sales volume of the top 20 products in sales exceeds 40 billion yuan, of which 19 drugs have sales of 1 billion yuan or more, and 3 are more than 3 billion yuan, namely Anroti Hydrochloride from Chia Tai Tianqing Pharmaceutica.
Ni Capsule, Hengrui Medicine's camrelizumab for injection, Sansheng Pharmaceutical's recombinant human thrombopoietin injection (TPIA.
In addition, it is worth mentioning that with the help of medical insurance, the sales of Cinda's sintilimab injection in 2021 will also reach nearly 3 billion yu.
Specifically, Chia Tai Tianqing Pharmaceutical's Anlotinib Hydrochloride Capsules was approved for marketing in May 2018, and was included in the National Medical Insurance Category B catalog through negotiation in the same year, and 5 indications have been achieved so f.
According to data from Min.
com, Anlotinib became a blockbuster as soon as it was list.
Its domestic sales exceeded 700 million yuan in its first year of listing (about half a yea.
It will exceed 4 billion yuan for the first time in 2020, and it will be expanded in 202 Hengrui Medicine's camrelizumab, the third domestically-made PD-1 mAb approved for marketing, was approved in May 201 Hengrui Medicine did not disclose the sales revenue of camrelizumab in its 2021 annual report, but the disclosed sales volume was 4143 million bottles, a year-on-year increase of 367
If calculated according to the medical insurance price of 2928 yuan/bottle, the sales revenue is about 141 billion yu.
Even with a year-on-year decline, it is still the one with higher sales among the four major domestic PD-1 mA.
According to the annual report released by 3SBio, in 2021, 3SBio achieved a total operating income of approximately RMB 38 billion, an increase of 12% over the same period last year; net profit attributable to the parent was RMB 65 billion, an increase of 96% over the same period last ye.
In 2021, 3SBio's main business revenue will maintain growth for 5 consecutive years, with a compound annual growth rate of 1
The sales revenue of core products will achieve strong double-digit growth, and the gross profit margin will be stable at over 8
Ability is outstandi.
Among them, TPIAO achieved sales revenue of 08 billion yuan, a year-on-year increase of 15%, with a market share of 7
Innovent Bio's 2021 annual report did not disclose the specific sales of the company's sintilimab, but it stated that "the company's annual operating income was 261 billion yuan, and the annual product revenue was about 001 billion yu.
The leading product Daboshu is on sa.
Both revenue and sales volume maintained strong growth, and other products also contributed to the strong growth in revenue, and the revenue contribution accounted for about 30% of the total annual product reven.
” Based on this calculation, the sales of Innovent Bio’s sintilimab in 2021 will account for the annual share of The total product revenue is about 70%, and the revenue is about 8 billion yuan, with a year-on-year growth rate of more than 2
In general, with the continuous improvement of the innovation capabilities of domestic pharmaceutical companies, more and more innovative drugs have begun to be launched at an accelerated pa.
However, the successful launch of innovative drugs is not the e.
What is more important is the second half, that is, to recover R&D costs through successful commercialization, and to obtain as much profit as possible, use it for more newer R&D projects, and promote the sustainable development of pharmaceutical compani.
The industry believes that from the current point of view, the road to commercialization of domestic innovative drugs can be expected in the future, but further efforts are needed in terms of indications and targets of innovative dru.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
